| 1 |
Ahmad M. Plant breeding advancements with “CRISPR-Cas” genome editing technologies will assist future food security. Front Plant Sci 2023;14. [DOI: 10.3389/fpls.2023.1133036] [Reference Citation Analysis]
|
| 2 |
Mazurov D, Ramadan L, Kruglova N. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles. Viruses 2023;15:690. [DOI: 10.3390/v15030690] [Reference Citation Analysis]
|
| 3 |
Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther 2023;8:36. [PMID: 36646687 DOI: 10.1038/s41392-023-01309-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Kluszczynska K, Czyz M. Extracellular Vesicles-Based Cell-Cell Communication in Melanoma: New Perspectives in Diagnostics and Therapy. Int J Mol Sci 2023;24. [PMID: 36674479 DOI: 10.3390/ijms24020965] [Reference Citation Analysis]
|
| 5 |
Guo H, Huang X. Engineered exosomes for future gene-editing therapy. Biomater Transl 2022;3:240-2. [PMID: 36846508 DOI: 10.12336/biomatertransl.2022.04.003] [Reference Citation Analysis]
|
| 6 |
Li Z, Liu Z, Wu J, Li B. Cell-Derived Vesicles for mRNA Delivery. Pharmaceutics 2022;14. [PMID: 36559192 DOI: 10.3390/pharmaceutics14122699] [Reference Citation Analysis]
|
| 7 |
Wu Q, Fu S, Xiao H, Du J, Cheng F, Wan S, Zhu H, Li D, Peng F, Ding X, Wang L. Advances in Extracellular Vesicle Nanotechnology for Precision Theranostics. Adv Sci (Weinh) 2023;10:e2204814. [PMID: 36373730 DOI: 10.1002/advs.202204814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Bhattacharjee R, Jana A, Nandi A, Sinha A, Bhattacharjee A, Mitra S, Kar S, Dey A, Kumar Singh S, Rajender Varma S, Kumar Panda P, Suar M, Suresh Verma K. Synergy of Nanocarriers with CRISPR-Cas9 in an Emerging Technology Platform for Biomedical Appliances: Current Insights and Perspectives. Materials & Design 2022. [DOI: 10.1016/j.matdes.2022.111415] [Reference Citation Analysis]
|
| 9 |
Kanu GA, Parambath JBM, Abu Odeh RO, Mohamed AA. Gold Nanoparticle-Mediated Gene Therapy. Cancers 2022;14:5366. [DOI: 10.3390/cancers14215366] [Reference Citation Analysis]
|
| 10 |
Hanson MA, Wester JC. Advances in approaches to study cell-type specific cortical circuits throughout development. Front Cell Neurosci 2022;16:1031389. [PMID: 36324861 DOI: 10.3389/fncel.2022.1031389] [Reference Citation Analysis]
|
| 11 |
Godbout K, Tremblay JP. Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy. Pharmaceutics 2022;14:2129. [PMID: 36297564 DOI: 10.3390/pharmaceutics14102129] [Reference Citation Analysis]
|
| 12 |
Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv 2022;8:eabp9435. [DOI: 10.1126/sciadv.abp9435] [Reference Citation Analysis]
|
| 13 |
Jeyaraman M, Muthu S, Shehabaz S, Jeyaraman N, Rajendran RL, Hong CM, Nallakumarasamy A, Packkyarathinam RP, Sharma S, Ranjan R, Khanna M, Ahn BC, Gangadaran P. Current understanding of MSC-derived exosomes in the management of knee osteoarthritis. Exp Cell Res 2022;418:113274. [PMID: 35810774 DOI: 10.1016/j.yexcr.2022.113274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 14 |
Mohammadhassan R, Tutunchi S, Nasehi N, Goudarziasl F, Mahya L. The Prominent Characteristics of the Effective sgRNA for a Precise CRISPR Genome Editing. CRISPR Technology [Working Title] 2022. [DOI: 10.5772/intechopen.106711] [Reference Citation Analysis]
|
| 15 |
Getahun YA, Ali DA, Taye BW, Alemayehu YA. Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System. VMRR 2022;Volume 13:173-190. [DOI: 10.2147/vmrr.s366533] [Reference Citation Analysis]
|
| 16 |
Hou S, Hasnat M, Chen Z, Liu Y, Faran Ashraf Baig MM, Liu F, Chen Z. Application Perspectives of Nanomedicine in Cancer Treatment. Front Pharmacol 2022;13:909526. [DOI: 10.3389/fphar.2022.909526] [Reference Citation Analysis]
|
| 17 |
Thongboonkerd V, Kanlaya R. The divergent roles of exosomes in kidney diseases: Pathogenesis, diagnostics, prognostics and therapeutics. Int J Biochem Cell Biol 2022;:106262. [PMID: 35787447 DOI: 10.1016/j.biocel.2022.106262] [Reference Citation Analysis]
|
| 18 |
Datta B, Paul D, Dey T, Pal S, Rakshit T. Importance of Extracellular Vesicle Derived RNAs as Critical Colorectal Cancer Biomarkers. ACS Bio Med Chem Au 2022;2:222-35. [DOI: 10.1021/acsbiomedchemau.1c00043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Dash HR, Arora M. CRISPR-CasB technology in forensic DNA analysis: challenges and solutions. Appl Microbiol Biotechnol 2022. [PMID: 35704073 DOI: 10.1007/s00253-022-12016-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 20 |
Ivanova E, Khan S. How Various Drug Delivery Methods Could Aid in the Translation of Genome Prime Editing Technologies. Genetics Research 2022;2022:1-8. [DOI: 10.1155/2022/7301825] [Reference Citation Analysis]
|
| 21 |
Wang L, Chen Y, Liu X, Li Z, Dai X. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. Front Oncol 2022;11:704999. [DOI: 10.3389/fonc.2021.704999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 22 |
Sohail M, Xie S, Zhang X, Li B. Methodologies in visualizing the activation of CRISPR/Cas: The last mile in developing CRISPR-Based diagnostics and biosensing – A review. Analytica Chimica Acta 2022. [DOI: 10.1016/j.aca.2022.339541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 23 |
Banerjee R, Smith J, Eccles MR, Weeks RJ, Chatterjee A. Epigenetic basis and targeting of cancer metastasis. Trends in Cancer 2021. [DOI: 10.1016/j.trecan.2021.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Claridge B, Lozano J, Poh QH, Greening DW. Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities. Front Cell Dev Biol 2021;9:734720. [PMID: 34616741 DOI: 10.3389/fcell.2021.734720] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 25 |
Chis AA, Dobrea CM, Rus LL, Frum A, Morgovan C, Butuca A, Totan M, Juncan AM, Gligor FG, Arseniu AM. Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy. Molecules 2021;26:5976. [PMID: 34641519 DOI: 10.3390/molecules26195976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 26 |
Asmamaw M, Zawdie B. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics 2021;15:353-61. [PMID: 34456559 DOI: 10.2147/BTT.S326422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 27 |
Kozovska Z, Rajcaniova S, Munteanu P, Dzacovska S, Demkova L. CRISPR: History and perspectives to the future. Biomed Pharmacother 2021;141:111917. [PMID: 34328110 DOI: 10.1016/j.biopha.2021.111917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
